Suppr超能文献

代谢和减重手术在肿瘤治疗前的可行性和结果。

The feasibility and outcomes of metabolic and bariatric surgery prior to neoplastic therapy.

机构信息

Department of Surgery, Whittington Hospital, London, UK; University College London, London, UK.

Department of Surgery, Mayo Clinic, Rochester, Minnesota.

出版信息

Surg Obes Relat Dis. 2024 Aug;20(8):717-728. doi: 10.1016/j.soard.2024.02.008. Epub 2024 Mar 7.

Abstract

BACKGROUND

Metabolic and bariatric surgery (MBS) is a potent intervention for addressing obesity-related medical conditions and achieving sustainable weight loss. Beyond its conventional role, MBS has demonstrated potential to serve as a transitional step for patients requiring various interventions. However, the implications of MBS in the context of neoplasia remain understudied.

OBJECTIVES

To explore the feasibility of MBS as a possible attempt to reduce surgical and treatment risks in patients with benign tumors or low-grade cancers.

SETTING

Multicenter review from twelve tertiary referral centers spanning 8 countries.

METHODS

A retrospective review of patients with a diagnosis of primary neoplasia, deemed inoperable or high-risk due to obesity, and receiving primary MBS prior to neoplastic therapy. Data encompassed baseline characteristics, neoplasia characteristics, MBS outcomes, and neoplastic therapy outcomes.

RESULTS

Thirty-seven patients (median age 52 years, 75.7% female, median BMI of 49.1 kg/m) were included. There were 9 distinct organs of origin of primary neoplasia, with the endometrium (43.2%) being the most common, followed by the pancreas, colon, kidney and breast. Sleeve gastrectomy (SG) was the most commonly performed MBS procedure (78.4%), with no MBS-related complications or mortalities reported over an average of 4.3 ± 3.9 years. Thirty-one patients (83.8%) eventually underwent neoplastic surgery, with a mean BMI decrease from 49.9 kg/m to 39.7 kg/m at surgery over an average of 5.8 ± 4.8 months. There were 2 (6.7%) documented mortalities associated with neoplastic surgical intervention.

CONCLUSIONS

This study highlights the potential feasibility of employing MBS prior to neoplastic therapy in patients with low-grade, less aggressive neoplasms in the context of obesity. This underscores the importance of providing a personalized, case-to-case multidisciplinary approach in the management of these patients.

摘要

背景

代谢和减重手术(MBS)是一种有效的干预措施,可用于解决肥胖相关的医疗状况并实现可持续的体重减轻。除了其传统作用外,MBS 已显示出作为需要各种干预措施的患者的过渡步骤的潜力。然而,MBS 在肿瘤学背景下的意义仍在研究中。

目的

探讨 MBS 作为一种可能的尝试,以降低肥胖患者良性肿瘤或低级别癌症患者的手术和治疗风险。

设置

来自 8 个国家的 12 个三级转诊中心的多中心回顾。

方法

回顾性分析诊断为原发性肿瘤的患者,由于肥胖而被认为无法手术或高风险,并在肿瘤治疗前接受原发性 MBS。数据包括基线特征、肿瘤特征、MBS 结果和肿瘤治疗结果。

结果

纳入 37 名患者(中位年龄 52 岁,75.7%为女性,中位 BMI 为 49.1kg/m²)。原发性肿瘤的起源器官有 9 个,子宫内膜(43.2%)最常见,其次是胰腺、结肠、肾脏和乳房。胃袖状切除术(SG)是最常进行的 MBS 手术(78.4%),平均随访 4.3±3.9 年后无 MBS 相关并发症或死亡率。31 名患者(83.8%)最终接受了肿瘤手术,平均 BMI 从 49.9kg/m²降至 39.7kg/m²,平均手术时间为 5.8±4.8 个月。有 2 例(6.7%)与肿瘤手术干预相关的死亡。

结论

本研究强调了在肥胖患者中,对于低度、侵袭性较低的肿瘤,在肿瘤治疗前使用 MBS 的潜在可行性。这突显了在这些患者的管理中提供个性化、病例到病例的多学科方法的重要性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验